Drug Profile
CYN 101
Alternative Names: CYN-101Latest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Cynvec
- Class Cancer vaccines; Oncolytic viruses
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ovarian cancer
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Ovarian cancer in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)
- 11 Jul 2016 Preclinical development is ongoing in USA